EDMONTON, April 12 /CNW/ - Ceapro Inc. (TSX-V: CZO) today announced the rebranding of its lead diabetes diagnostic technology as CeaProve(TM). "As a result of the 2004 pre-market activities, it became clear that our diabetes technology extended beyond accurate screening with results indicating applications in both diabetes AND pre-diabetes, for screening, diagnosis, and monitoring," said Mr. Oleh Hnatiuk, Acting Managing Director of Ceapro Technology Inc. "With this expansion of applications, we have branded our diabetes technology as CeaProve(TM). CeaProve(TM) is clearly a new product with use in new markets of pre-diabetes detection and diabetes prevention," Mr. Hnatiuk continued. "During 2004, we discovered new applications in the area of diabetes monitoring and drug dosage determination. We are more convinced than ever that CeaProve(TM) represents breakthrough technology that will occupy a critical place in global health and wellness strategies." This week, Ceapro will unveil CeaProve(TM) to the world at The First International Congress on Pre-diabetes and the Metabolic Syndrome, in Berlin, Germany, from April 13-16, 2005. The congress is dedicated to communicating the advances in the field and will serve as a platform in which screening and intervention will be presented and evaluated. Further information can be found on the congress' website at: www.kenes.com/pre-diabetes. 2004 Financial Results and Annual and Special Meeting Ceapro will release its 2004 financial results on or before April 29, 2005. The Company's annual report, containing Management's Discussion and Analysis and Audited Financial Statements, will be mailed to shareholders on or about May 2, 2005. Ceapro's annual and special meeting of shareholders will be held on Wednesday, June 1, 2005, at Lister Centre, University of Alberta, at 3:00 p.m. MDT About CeaProve(TM) CeaProve(TM) is a simple, cost effective, and rapid point-of-care tool to detect the elevated blood glucose levels indicative of pre-diabetic and diabetic conditions. CeaProve(TM) consists of calibrated wafers made from a proprietary formulation of proteins, fats, and complex carbohydrates that are consumed with a glass of water after an overnight fast. A quick analysis of the blood, using one of many standard glucose meters presently on the market, provides an on-the-spot indication of elevated blood glucose levels. Ceapro is pursuing several strategies to position CeaProve(TM) for sale and distribution to the public. These include selling the product over the counter at Canadian pharmacies and a global partnership strategy for international markets. About Ceapro Inc. Ceapro Inc., an innovation-driven biotechnology company, develops and commercializes organic products for medical, cosmetic, and animal health industries using proprietary technology and natural, renewable resources. Based in Edmonton, Alberta, Ceapro is one of Alberta Venture's Fastest Growing Companies for 2004 and 2005 and is one of Profit Magazine's Next 100 Companies. Ceapro is also the recipient of the ASTech Award for Outstanding Commercial Achievement for companies with annual sales of less than $25 million. Ceapro's shares trade on the TSX Venture Exchange under the symbol CZO. To learn more about Ceapro, log on to our website at www.ceapro.com. Shares Outstanding: 36,355,950, Recent Close: $0.275. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the accuracy of this news release. This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements. Although the Company believes that the forward- looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. %SEDAR: 00010110E
Ceapro rebrands patented diabetes technology as CeaProve(TM)
Later from Ceapro
- Ceapro announces new Controller
- Ceapro receives further investment from AVAC Ltd.
- Ceapro announces 2004 financial results
- Ceapro to present at BioFinance conference
- Ceapro Announces Highlights of Today's Annual General and Special Meeting
Follow Ceapro into a list and get an email when it puts out news.
Follow Ceapro